Treatment of multiple myeloma in combination with dexamethasone

25 mg daily on days 1–21 of a 28 day cycle; reduce dose if patient has neutropenia or thrombocytopenia; see data sheet

Molecular weight :259.3

%Protein binding :22.7–29.2

%Excreted unchanged in urine : 65–85

Volume of distribution (L/kg) :86 litres

half-life – normal/ESRD (hrs) :3.5/>9

30–50 10 mg daily, increasing to 15 mg after 2 cycles if patient is not responding<30 15 mg every 48 hours

CAPD :Probably dialysed. 15 mg 2–3 times a week

HD :Probably dialysed. 15 mg 3 times a week post dialysis

HDF/high flux :Probably dialysed. 15 mg 3 times a week post dialysis

CAV/VVHD :Probably dialysed. Dose as in GFR=30–50 mL/min

Potentially hazardous interactions with other drugsCardiac glycosides: possibly increases concentration of digoxin

–

Oral

–

–

May cause acute renal failure – monitor renal function during treatment. Patients with renal impairment are more likely to develop side effects